- Home
- CELZ vs APM Comparison
CELZ vs APM Comparison
Compare CELZ & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELZ | APM |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 10.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CELZ | APM |
|---|---|---|
| Price | $2.20 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 77.4K | 49.3K |
| Earning Date | 11-07-2025 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.69 | $0.69 |
| 52 Week High | $6.90 | $7.49 |
Technical Indicators
Market Signals| Indicator | CELZ | APM |
|---|---|---|
| Relative Strength Index (RSI) | 36.45 | 38.91 |
| Support Level | $2.03 | $1.08 |
| Resistance Level | $2.25 | $1.23 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 20.36 | 25.69 |
Price Performance
Historical ComparisonAbout CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.